|
|
|
|
| There’s been great progress in establishing platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for non-vaccine products? Secure your spot for Advancing RNA Live’s next digital panel discussion on the current known unknowns (and unknown unknowns) about our mRNA therapeutics candidates that make adopting the traditional QbD approach complicated. Registration is free thanks to the support of Roche Custom Biotech. |
|
|
|
|
As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech; the therapeutic proposition of circular, or "O", RNA and why it holds great potential to linear RNA constructs; the novel platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy; LNP complexity, and a whole lot more. |
|
|
|
| Streamlining Upstream Plasmid DNA Manufacturing | White Paper | By Kayla J. Spivey, Thermo Fisher Scientific | Here we will discuss the scalable process workflow solutions available from initial R&D investment to clinical testing and commercialization. |
|
|
|
|
|
|
|
| Clinical Research As A Delicate Ecosystem | Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors. Entrust that your program is in hands you can rely on, where integrity is paramount, and excellence is the standard. |
|
|
ADDITIONAL FEATURED EDITORIALS |
|
|
|
By L. Salazar-Fontana and Daniela Drago, NDA Partners | Variability is inherent to biologics manufacturing. The trick is to catch it quickly and prevent product quality drift. That’s where the new ICH Q14 comes in. |
|
|
|
The experts on this Advancing RNA Live panel share their takeaways from several audience poll questions revealing which RNA molecules are getting the lion’s share of attention/development today. |
|
|
.png){kind=logo}
